R V Chandra1, T M Leslie-Mazwi2, B P Mehta2, A J Yoo3, J D Rabinov3, J C Pryor4, J A Hirsch3, R G Nogueira5. 1. From the Neuroradiology and Neurovascular Surgery Services, Departments of Diagnostic Imaging and Surgery (R.V.C.), Monash University, Melbourne, Victoria, Australia. 2. Neuroendovascular Service (T.M.L.-M., B.P.M., A.J.Y., J.D.R., J.A.H.) Department of Neurology (T.M.L.-M., B.P.M.). 3. Neuroendovascular Service (T.M.L.-M., B.P.M., A.J.Y., J.D.R., J.A.H.) Department of Radiology (A.J.Y., J.D.R., J.A.H.), Division of Diagnostic Neuroradiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. 4. Department of Interventional Neuroradiology (J.C.P.), Boston University, Boston, Massachusetts. 5. Neuroendovascular and Neurocritical Care Services and Neurology, Neurosurgery, and Radiology (R.G.N.), Marcus Stroke and Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, Georgia. raul.g.nogueira@emory.edu.
Abstract
BACKGROUND AND PURPOSE: Endovascular therapy with liquid embolic agents is a common treatment strategy for cranial dural arteriovenous fistulas. This study evaluated the long-term effectiveness of transarterial Onyx as the single embolic agent for curative embolization of noncavernous cranial dural arteriovenous fistulas. MATERIALS AND METHODS: We performed a retrospective review of 40 consecutive patients with 41 cranial dural arteriovenous fistulas treated between March 2006 and June 2012 by using transarterial Onyx embolization with intent to cure. The mean age was 57 years; one-third presented with intracranial hemorrhage. Most (85%) had cortical venous drainage. Once angiographic cure was achieved, long-term treatment effectiveness was assessed with DSA and clinical follow-up. RESULTS: Forty-nine embolization sessions were performed; 85% of cranial dural arteriovenous fistulas were treated in a single session. The immediate angiographic cure rate was 95%. The permanent neurologic complication rate was 2% (mild facial palsy). Thirty-five of the 38 patients with initial cure underwent short-term follow-up DSA (median, 4 months). The short-term recurrence rate was only 6% (2/35). All patients with occlusion at short-term DSA undergoing long-term DSA (median, 28 months) had durable occlusion. No patient with long-term clinical follow-up (total, 117 patient-years; median, 45 months) experienced hemorrhage. CONCLUSIONS: Transarterial embolization with Onyx as the single embolic agent results in durable long-term cure of noncavernous cranial dural arteriovenous fistulas. Recurrence rates are low on short-term follow-up, and all patients with angiographic occlusion on short-term DSA follow-up have experienced a durable long-term cure. Thus, angiographic cure should be defined at short-term follow-up angiography instead of at the end of the final embolization session. Finally, long-term DSA follow-up may not be necessary if occlusion is demonstrated on short-term angiographic follow-up.
BACKGROUND AND PURPOSE: Endovascular therapy with liquid embolic agents is a common treatment strategy for cranial dural arteriovenous fistulas. This study evaluated the long-term effectiveness of transarterial Onyx as the single embolic agent for curative embolization of noncavernous cranial dural arteriovenous fistulas. MATERIALS AND METHODS: We performed a retrospective review of 40 consecutive patients with 41 cranial dural arteriovenous fistulas treated between March 2006 and June 2012 by using transarterial Onyx embolization with intent to cure. The mean age was 57 years; one-third presented with intracranial hemorrhage. Most (85%) had cortical venous drainage. Once angiographic cure was achieved, long-term treatment effectiveness was assessed with DSA and clinical follow-up. RESULTS: Forty-nine embolization sessions were performed; 85% of cranial dural arteriovenous fistulas were treated in a single session. The immediate angiographic cure rate was 95%. The permanent neurologic complication rate was 2% (mild facial palsy). Thirty-five of the 38 patients with initial cure underwent short-term follow-up DSA (median, 4 months). The short-term recurrence rate was only 6% (2/35). All patients with occlusion at short-term DSA undergoing long-term DSA (median, 28 months) had durable occlusion. No patient with long-term clinical follow-up (total, 117 patient-years; median, 45 months) experienced hemorrhage. CONCLUSIONS: Transarterial embolization with Onyx as the single embolic agent results in durable long-term cure of noncavernous cranial dural arteriovenous fistulas. Recurrence rates are low on short-term follow-up, and all patients with angiographic occlusion on short-term DSA follow-up have experienced a durable long-term cure. Thus, angiographic cure should be defined at short-term follow-up angiography instead of at the end of the final embolization session. Finally, long-term DSA follow-up may not be necessary if occlusion is demonstrated on short-term angiographic follow-up.
Authors: James David Rabinov; Albert J Yoo; Christopher S Ogilvy; Bob S Carter; Joshua A Hirsch Journal: J Neurointerv Surg Date: 2012-05-01 Impact factor: 5.836
Authors: Yin C Hu; C Benjamin Newman; Shervin R Dashti; Felipe C Albuquerque; Cameron G McDougall Journal: J Neurointerv Surg Date: 2011-01-06 Impact factor: 5.836
Authors: Michael F Stiefel; Felipe C Albuquerque; Min S Park; Shervin R Dashti; Cameron G McDougall Journal: Neurosurgery Date: 2009-12 Impact factor: 4.654
Authors: Anna Piippo; Aki Laakso; Karri Seppä; Jaakko Rinne; Juha E Jääskeläinen; Juha Hernesniemi; Mika Niemelä Journal: J Neurosurg Date: 2013-04-19 Impact factor: 5.115
Authors: R G Nogueira; G Dabus; J D Rabinov; C J Eskey; C S Ogilvy; J A Hirsch; J C Pryor Journal: AJNR Am J Neuroradiol Date: 2007-11-01 Impact factor: 3.825
Authors: C Cognard; Y P Gobin; L Pierot; A L Bailly; E Houdart; A Casasco; J Chiras; J J Merland Journal: Radiology Date: 1995-03 Impact factor: 11.105
Authors: Collin M Torok; Raul G Nogueira; Albert J Yoo; Thabele M Leslie-Mazwi; Joshua A Hirsch; Christopher J Stapleton; Aman B Patel; James D Rabinov Journal: Interv Neuroradiol Date: 2016-08-16 Impact factor: 1.610
Authors: Yosuke Akamatsu; Santiago Gomez-Paz; Daniel A Tonetti; David Vergara-Garcia; Viraj M Moholkar; Anna Luisa Kuhn; Kohei Chida; Jasmeet Singh; Katyucia de Macedo Rodrigues; Francesco Massari; Justin M Moore; Christopher S Ogilvy; Ajit S Puri; Ajith J Thomas Journal: J Cerebrovasc Endovasc Neurosurg Date: 2022-07-07
Authors: Rene A Colorado; Marcelo Matiello; Hyun-Sik Yang; James D Rabinov; Aman Patel; Joshua A Hirsch; Ram Chavali; Thabele M Leslie-Mazwi Journal: Interv Neurol Date: 2018-03-27
Authors: D F Vollherbst; C Herweh; S Schönenberger; F Seker; S Nagel; P A Ringleb; M Bendszus; M A Möhlenbruch Journal: AJNR Am J Neuroradiol Date: 2019-11-21 Impact factor: 3.825
Authors: W M T Jolink; J M C van Dijk; C J J van Asch; G A P de Kort; A Algra; R J M Groen; G J E Rinkel; C J M Klijn Journal: J Neurol Date: 2015-09-26 Impact factor: 4.849